RESULT OF THE BUY-BACK OFFER

Udgivet den 14-02-2017  |  kl. 09:00  |  

Nasdaq Copenhagen
Nikolaj Plads 6
DK-1067 Copenhagen K   

Frederikssund, 14 February 2017
ANNOUNCEMENT NO. 3/2017

 

 

RESULT OF THE BUY-BACK OFFER

On 27 January 2017, Cemat A/S announced an offer to the shareholders to buy back the Company's own shares at a fixed price of DKK 0,352 per share.

At the end of the offer period, the Company has received 294,313,765 acceptances from shareholders representing 54.1% of the shares in the Company.

At the Company's general meeting held on 24 October 2016, the Board of Directors was authorised to buy back up to 337,993,060 shares, equivalent to around 62% of the shares in the Company.

As the number of shares tendered to the Company represents fewer shares than provided for under the authorisation, the number of shares purchased will not be reduced.

Immediately following this announcement, the Company will convene an annual general meeting to be held on 8 March 2017 for the adoption, among other things, of a capital reduction equivalent to the acceptances received. If the capital reduction is adopted, and if no significant claims are filed by creditors against the Company in the subsequent 4-week period (statutory notice), the Company is expected to complete and apply for registration of the capital reduction with the Danish Business Authority after expiry of the 4-week period on 11 April 2017.

Completion and settlement of the buy-back offer is expected to take place after the 4-week period on 11 April 2017.

Cemat A/S

Jens Borelli-Kjær

Chairman of the Board of Directors

 

This announcement has been issued in Danish and English. In case of any inconsistencies, the Danish version will prevail.

Unsubscribe announcements: investor@cemat.dk.

Vedhæftede filer:

03-17 Result of share buy-back offer.pdf

Udgivet af: NPinvestordk

Seneste nyheder

09:17 Aktier/åbning: Zealand tager gigantisk kurshop på milliardaftale
08:54 Obligationer/åbning: Flad renteudvikling før vigtig inflationsrapport
08:46 Zealands aktiekurs kan stige mere end 30 pct. spår Jefferies
08:43 Zealand Pharma har stor tiltro til kombination mellem kronjuvel og mulig "best in class"-molekyle
08:29 Råvarer: Svagere dollar sender oliepriserne i opadgående retning
08:22 Aktier/tendens: Zealand har udsigt til topplacering i ventet grønt marked
08:17 Zealand Pharma har fundet en partner til Petrelintid: Topchef ser enormt potentiale i overskudsdeling
08:00 Tysk våbenproducent skruer lidt ned for salgsvæksten i år efter rekord i 2024
07:37 Zealand har fået gigantaftale med wauw-effekt i hus mener Nordnet
07:32 Obligationer/tendens: Nye rentestigninger i sigte med fokus på amerikansk inflation
07:22 Zealand Pharma finder schweizisk partner til sin kronjuvel
07:06 Novo får skåret kursmålet hos Jefferies efter skuffende Cagrisema-tal
06:58 EU vil indføre nye afgifter som svar på amerikansk told
06:49 DSV får købsanbefaling hos Jefferies: Ser positivt på strategi og Schenker-opkøb
06:38 Genmab får skåret kursmålet hos Morgan Stanley efter Hexabody-afgørelse
06:37 Asien: Bekymrede investorer forsøger at finde fodfæste
06:35 EU vil lægge told på varer fra USA for 26 mia. euro.
06:34 Ukraine støtter forslag om våbenhvile - USA genoptager militær støtte
06:34 Trump dropper toldfordobling - Ontario suspenderer eksporttold
06:34 Nordea får kursmålet sænket med 5 pct. hos Citi